If you’ve been offered PRP (platelet-rich plasma) or stem cell injections for joint pain, the short answer is: PRP has modest, condition-specific evidence and is not FDA-approved as a drug, while stem cell therapy for joints has little reliable evidence and is largely unapproved and unregulated as a treatment. Neither is a guaranteed fix, and the two get marketed together far more often than the evidence or the regulatory picture actually supports. The rest of this guide walks through how to evaluate a specific offer, what “FDA registered” actually means in this space, what clinical guidelines say, and what to ask before you spend money on either one.
Evaluate the Precise Product and Indication Being Offered
“Regenerative medicine” is a marketing umbrella, not a single product. Before you evaluate any PRP or stem cell offer, pin down three specifics the clinic should be able to answer without hesitation:
- Exactly what’s being injected. PRP is your own blood, spun down to concentrate platelets — no cells are added or cultured. Stem cell products vary widely: bone marrow aspirate, adipose (fat) tissue, umbilical cord or amniotic tissue products, and whether the cells are “minimally manipulated” or expanded/cultured in a lab.
- The exact joint and condition. Evidence for PRP in knee osteoarthritis does not transfer to PRP in ankle osteoarthritis, and evidence for one tendon condition doesn’t transfer to another — the data is condition-specific, not a blanket “PRP works for joints” claim.
- Whether the product itself is FDA-cleared, or just the device. A clinic may say their system is “FDA-cleared” when what’s cleared is the centrifuge or separator device used to prepare the PRP — not a claim that PRP itself is an approved treatment for your condition.
A vague answer to any of these — or marketing language that treats PRP and stem cells as interchangeable “regenerative” options — is a reason to ask more questions before booking.
Does FDA Registration Mean Approval?
No, and this is the single most misunderstood point in this category. Many clinics are registered with the FDA as tissue establishments under federal tissue-product regulations — that’s a listing requirement, not a review of safety or effectiveness. Here’s how the two therapies actually sit under federal regulation:
- PRP is generally not regulated as a drug when it’s your own blood, processed and re-injected into you in the same procedure — this falls under what’s called the “same surgical procedure exception.” The device used to separate it may carry FDA clearance as a blood-processing device, but there is no FDA-approved PRP drug for joint pain specifically.
- Stem cells for orthopedic use are in a different position. The FDA has stated it does not consider most orthopedic stem cell applications to meet the definition of “homologous use” — meaning the cells aren’t being used for the same basic function they perform in their original location in the body. That matters because it’s one of the criteria a product must meet to qualify for the lighter-touch regulatory exemption available to minimally manipulated tissue products. When a stem cell product doesn’t meet that bar, it legally needs premarket approval as a biologic — and the FDA has issued warning letters to clinics marketing unapproved orthopedic stem cell products on exactly this basis.
In practice: ask whether the specific product has gone through FDA premarket review for your indication, not just whether the clinic or device is “FDA registered.” Those are two different questions with two different answers.
What Do Guideline Recommendations Say?
Clinical guidelines are more cautious than most marketing material, and they don’t treat PRP and stem cells the same way:
- The American Academy of Orthopaedic Surgeons’ 2026 ankle osteoarthritis guideline moderately recommends against routine use of intra-articular PRP for ankle OA, citing no sustained benefit over saline placebo through 12 months — and found no reliable evidence to support stem cell injections for the same condition.
- Hip and knee osteoarthritis guidelines have landed differently by product: PRP for knee and/or hip OA is typically given a conditional, neutral recommendation (not a clear “yes,” not a clear “no”), while stem cell therapy for knee and/or hip OA carries a strong recommendation against offering it.
- A 2026 guidance statement from the American Academy of Physical Medicine and Rehabilitation on PRP for knee osteoarthritis takes a middle path — it supports considered, evidence-informed use after standard conservative therapies have been tried, while explicitly noting the guidance is meant to inform clinical judgment, not replace it.
The pattern across guidelines: PRP earns cautious, condition-dependent consideration in some joints; stem cell therapy for joint pain does not currently have guideline support.
What Evidence Supports the Exact Service You’re Being Offered?
“Evidence supports PRP” is not a complete sentence — the evidence strength changes by joint and condition, and you should expect your provider to be specific when you ask:
- Knee osteoarthritis and lateral epicondylitis (“tennis elbow”) are the two conditions where PRP has the most support in practice-recommendation reviews, though the evidence is generally rated as consensus/usual-practice strength rather than high-certainty trial evidence — some systematic reviews note enough variability in study design and injection technique that they stop short of a clear recommendation for knee OA specifically.
- PRP for Achilles tendinopathy is specifically flagged in evidence reviews as not supported by current clinical research.
- Stem cell therapy for joint conditions generally lacks the randomized, controlled evidence base that PRP has — guideline bodies describe the evidence as insufficient or unreliable rather than simply “promising but early.”
Before any injection, it’s reasonable to ask the provider: What population was studied, what was it compared against (saline, corticosteroid, nothing), how long were outcomes tracked, and what harms were reported? A provider who can answer precisely is a different conversation than one who answers with testimonials.
Joint-Function Worksheet: Prepare for an Appropriate Assessment
Before you consult anyone about PRP or stem cell injections, write out the following — it gives a clinician the information needed to evaluate whether your joint pain is even a reasonable candidate for these therapies:
- Painful movement: Which specific motions or activities trigger or worsen the pain?
- Swelling, warmth, and timing: Is the joint swollen or warm to the touch, and does that come and go or stay constant?
- Daily activity limit: What can you no longer do, or do only with modification, because of this joint?
- What’s helped or worsened it: Rest, ice, specific exercises, prior injections, medications — what changed the pain, in either direction?
- Questions for your assessment: Has imaging been done? What’s the working diagnosis? What conservative options haven’t been tried yet?
If you notice new or worsening numbness, weakness, or loss of function in the joint or limb, signs of infection (fever, spreading redness, warmth with worsening swelling), a recent injury, or symptoms suggesting a vascular problem (coldness, color change, loss of pulse), that calls for prompt medical evaluation — not a regenerative-medicine consultation, and not a wait-and-see approach.
Useful Alternatives and Next Steps
PRP and stem cells are not the first or only options for joint pain, and guidelines consistently point to conservative care as the starting point:
- Structured physical therapy and targeted strengthening, which remain standard first-line care across most joint conditions.
- Weight management, where relevant, which reduces mechanical load on weight-bearing joints like the knee and hip.
- NSAIDs or acetaminophen, used as directed and with attention to any contraindications.
- Corticosteroid injections, which have a longer track record and more established guideline support for short-term symptom relief in several joints.
If you’re also looking at non-injection approaches to chronic inflammation, our guide to peptides and inflammation covers a different set of options worth understanding before — or instead of — an injection-based procedure.
If PRP or stem cells are still on the table after conservative care, bring your completed worksheet and the questions above to that conversation — and treat “FDA registered” as the start of a question, not the end of one.
This article is for general information purposes only and does not constitute medical advice. It does not diagnose any condition. Consult a qualified healthcare provider for evaluation of joint pain, especially before pursuing any injection-based procedure.
Keep reading